ViiV's HIV candidate meets in Phase III

ViiV Healthcare Ltd. (Brentford, U.K.) said oral fostemsavir (GSK3684934) met the primary endpoint in the Phase III BRIGHTE trial to treat heavily treatment-experienced patients with HIV-1 infection. In the trial's randomized cohort, fostemsavir led to a significantly greater mean reduction in HIV-1 viral load from baseline to day eight vs. placebo (0.79 vs. 0.17 log10 copies/mL, p<0.0001). Data were presented at the European AIDS Conference in Milan.

BRIGHTE enrolled 371 patients who failed antiretroviral (ARV) agents in at least four of the six available ARV classes and separated patients into a randomized or non-randomized cohort...